Litigation Details for Acadia Pharmaceuticals Inc. v. Aurobindo Pharma Ltd. (Fed. Cir. 2024)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2024-01-29
Court	Court of Appeals for the Federal Circuit	Date Terminated
Cause		Assigned To
Jury Demand		Referred To
Patents	7,115,634; 7,601,740; 9,566,271
Link to Docket	External link to docket

The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2024-05-29	13		ABBREVIATIONS ’740 patent U.S. Patent No. 7,601,740 (Appx79-108) ’271 patent …ASSERTED CLAIMS Asserted claim 26 of U.S. Patent No. 7,601,740 depends from claim 22: 22. A compound having… U.S. Patent No. 9,566,271 (Appx109-135) ’462 patent U.S. Patent No. 7,732,462 ’561 application… second patent on subject matter not patentably distinct from the claims of the first patent, … [a] patent… a later-filed patent that are not patentably distinct from the earlier[-]filed patent.” SimpleAir, Inc	External link to document
2024-03-29	9		Rye, NH (US); 7,115,634 B2 10/2006 Thurieau et al. … U.S. Patent No. 9,566,271 (“the ’271 patent”) cannot be an obviousness-type double patenting (“OTDP…challenged ’740 patent and the OTDP reference ’271 patent. Appx065. Claim 26 of the ’740 patent is directed…whereas the ’740 patent received a 980-day patent term adjustment (“PTA”), the ’271 patent does not have… “A later patent claim is not patentably distinct from an earlier patent claim if the later	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document